FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1883-1888 December 27, 2001 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Paglia, F. Related Article by Paglia, F. PubMed Citation

Tumor-induced osteomalacia (also known as oncogenic osteomalacia)¹ is a rare disorder characterized by phosphaturia, hypophosphatemia, and osteomalacia mimicking the clinical phenotype of either X-linked² or autosomal dominant³ hereditary hypophosphatemic rickets. Tumor-induced osteomalacia develops because of tumors that are predominantly of benign mesenchymal origin⁴ but that may occasionally be malignant, as was recently reported.⁵ Surgical removal of the tumor relieves all symptoms. Hemangiopericytoma is the most dominant histologic entity in tumor-induced osteomalacia.^4,6 Paraneoplastic secretion by the tumor of an unknown factor or factors — termed "phosphatonins" — causing renal tubular phosphate wasting has been proposed as the pathogenic mechanism.⁷

We describe . . . [Full Text of this Article]

Case Report

Methods

Assays

Imaging Studies and Octreotide Therapy

Expression of Somatostatin-Receptor Subtypes

Expression of mRNA for Matrix Extracellular Phosphoglycoprotein and Fibroblast Growth Factor 23

Results

Discussion

Source Information

From the Division of Endocrinology, Metabolism, and Molecular Medicine, Medizinische Poliklinik (J.S., K.E., F.J.); and the Departments of Pathology (J.M.), Orthopedic Surgery (J.E., C.H., N.S.), Nuclear Medicine (E.W.), and Radiology (G.S., W.K.), University of Würzburg — both in Würzburg; the Division of Endocrinology of the Department of Internal Medicine I, University of Regensburg, Regensburg (K.-D.P.); and Tirschenreuth (H.R.) — all in Germany.

Address reprint requests to Dr. Jakob at the Division of Endocrinology, Metabolism, and Molecular Medicine, Medizinische Poliklinik, University of Würzburg, Klinikstr. 6-8, 97070 Würzburg, Germany, or at jakob.medpoli@mail.uni-wuerzburg.de.

References

Related Letters:

Octreotide for Tumor-Induced Osteomalacia
Paglia F., Dionisi S., Minisola S., Seufert J., Jakob F.
Extract | Full Text | PDF  
N Engl J Med 2002; 346:1748-1749, May 30, 2002. Correspondence

This article has been cited by other articles:

• Mussig, K., Oksuz, M. O., Pfannenberg, C., Adam, P., Zustin, J., Beckert, S., Petersenn, S. (2009). Somatostatin Receptor Expression in an Epitheloid Hemangioma Causing Oncogenic Osteomalacia. J. Clin. Endocrinol. Metab. 94: 4123-4124 [Full Text]  
• David, V., Martin, A., Hedge, A.-M., Rowe, P. S. N. (2009). Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator. Endocrinology 150: 4012-4023 [Abstract] [Full Text]  
• CHUA, S C, O'CONNOR, S R, WONG, W L, GANATRA, R H (2008). Solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br. J. Radiol. 81: e110-e114 [Abstract] [Full Text]  
• van Boekel, G., Ruinemans-Koerts, J., Joosten, F., Dijkhuizen, P., van Sorge, A., de Boer, H. (2008). Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 158: 431-437 [Abstract] [Full Text]  
• Hannan, F. M, Athanasou, N. A, Teh, J., Gibbons, C. L M H, Shine, B., Thakker, R. V (2008). Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. Eur J Endocrinol 158: 265-271 [Abstract] [Full Text]  
• Paul, S., Kurtz, M., Mentzer, S. J. (2007). Osteomalacia associated with a fibroblast growth factor 23 secreting chest wall tumor. J. Thorac. Cardiovasc. Surg. 134: 803-805 [Full Text]  
• Jan de Beur, S. M. (2005). Tumor-Induced Osteomalacia. JAMA 294: 1260-1267 [Abstract] [Full Text]  
• Auethavekiat, P., Roberts, J. R., Biega, T. J., Toney, M. O., Christensen, R. S., Belnap, C. M., Berenberg, J. L. (2005). Difficult Diagnostic Cases: CASE 3. Oncogenic Osteomalacia Associated With Hemangiopericytoma Localized by Octreotide Scan. JCO 23: 3626-3628 [Full Text]  
• Bresler, D., Bruder, J., Mohnike, K., Fraser, W. D, Rowe, P. S N (2004). Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183: R1-R9 [Abstract] [Full Text]  
• Bai, X., Miao, D., Li, J., Goltzman, D., Karaplis, A. C. (2004). Transgenic Mice Overexpressing Human Fibroblast Growth Factor 23 (R176Q) Delineate a Putative Role for Parathyroid Hormone in Renal Phosphate Wasting Disorders. Endocrinology 145: 5269-5279 [Abstract] [Full Text]  
• Seboek, D., Linscheid, P., Zulewski, H., Langer, I., Christ-Crain, M., Keller, U., Muller, B. (2004). Somatostatin Is Expressed and Secreted by Human Adipose Tissue upon Infection and Inflammation. J. Clin. Endocrinol. Metab. 89: 4833-4839 [Abstract] [Full Text]  
• Ebert, R., Jovanovic, M., Ulmer, M., Schneider, D., Meissner-Weigl, J., Adamski, J., Jakob, F. (2004). Down-Regulation by Nuclear Factor {kappa}B of Human 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Promoter. Mol. Endocrinol. 18: 2440-2450 [Abstract] [Full Text]  
• Rowe, P. S.N. (2004). THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX. CROBM 15: 264-281 [Abstract] [Full Text]  
• Takeuchi, Y., Suzuki, H., Ogura, S., Imai, R., Yamazaki, Y., Yamashita, T., Miyamoto, Y., Okazaki, H., Nakamura, K., Nakahara, K., Fukumoto, S., Fujita, T. (2004). Venous Sampling for Fibroblast Growth Factor-23 Confirms Preoperative Diagnosis of Tumor-Induced Osteomalacia. J. Clin. Endocrinol. Metab. 89: 3979-3982 [Abstract] [Full Text]  
• Oberg, K., Kvols, L., Caplin, M., Delle Fave, G., de Herder, W., Rindi, G., Ruszniewski, P., Woltering, E. A., Wiedenmann, B. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15: 966-973 [Abstract] [Full Text]  
• Nelson, A. E., Bligh, R. C., Mirams, M., Gill, A., Au, A., Clarkson, A., Juppner, H., Ruff, S., Stalley, P., Scolyer, R. A., Robinson, B. G., Mason, R. S., Bligh, P. C. (2003). Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia. J. Clin. Endocrinol. Metab. 88: 4088-4094 [Abstract] [Full Text]  
• Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, O., Oba, K., Yang, I. M., Miyauchi, A., Econs, M. J., Lavigne, J., Juppner, H. (2003). Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia. NEJM 348: 1656-1663 [Abstract] [Full Text]  
• Carpenter, T. O. (2003). Oncogenic Osteomalacia -- A Complex Dance of Factors. NEJM 348: 1705-1708 [Full Text]  
• Silve, C., Beck, L. (2002). Is FGF23 the long sought after phosphaturic factor phosphatonin?. Nephrol Dial Transplant 17: 958-961 [Full Text]  
• Paglia, F., Dionisi, S., Minisola, S., Seufert, J., Jakob, F. (2002). Octreotide for Tumor-Induced Osteomalacia. NEJM 346: 1748-1749 [Full Text]